AGOURA HILLS, Calif. - Oncotelic Therapeutics, Inc. ('Oncotelic' or the 'Company') (OTCQB:OTLC), a leading developer of TGF-? therapeutics for oncology and COVID-19, reports positive top line data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal against COVID-19 in India.

'We thank our investigators, patients, collaborators, and investors for their support in completion of ARTI-19, despite the challenging health environment in India, due to the recent surge in COVID-19 cases in India. Despite the challenges, we are working diligently to lock the dataset to complete our regulatory submission.' said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

PulmoHeal is being developed by Oncotelic, in partnership with Windlas Biotech Private Limited. We have shown that the active component of PulmoHeal is active against the influenza virus, which is consistent with the broad-spectrum activity for PulmoHeal and which is confirmed by its reported activity against multiple variants of SARS-CoV2: WT (USA/WA12020) SARS-CoV-2 and variants, B1.1.7 and B1.351. The top line data for ARTI-19 are as follow:

No adverse events were reported that required discontinuation of treatment.

PulmoHeal, when added to the standard of care (SOC), accelerated the recovery of patients with mild to moderate COVID-19, across all COVID-19 symptoms examined.

91% of WHO-4 pts achieved a reduction to WHO-3 on the first few doses of PulmoHeal, p = 0.0037 (n= 56 / PulmoHeal + SOC vs n= 25 / SOC).

All vitals were normalized by the end of the 28-day monitoring period.

Most importantly, oxygen (O2) saturation fully recovered by day-28 with PulmoHeal + SOC (p=0.0003), but not with SOC alone (p=ns).

The number of patients with O2 saturation < 95% reduced by 91% when treated with PulmoHealTM + SOC.

In contrast, treatment with SOC alone only resulted in a 31% reduction.

Similarly, respiratory rate fully recovered by day-28 with PulmoHeal + SOC (p

(C) 2021 Electronic News Publishing, source ENP Newswire